The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. LEARN MORE ABOUT THE PROCEDURE BY THE NUMBERS | NeoChord in the World 0 Countries 0+ Study Patients 0+ Publications
Show more
See More
Aug 14, 2018 . The NeoChord device, in illustration, is inserted in the beating heart through a small incision, guided by echocardiography “While the heart is beating, you make a small incision under the patient’s left nipple, insert the device, and implant the artificial chords to the mitral valve,” says Dr. El-Eshmawi, the site Principal Investigator for the study.
Show more
See More
Nov 04, 2018 . The NeoChord device is directed towards the mitral valve plane using 2D-TEE guidance (X-plane with ME LAX and MC views) avoiding interference with adjacent subvalvular structures. During 2D-TEE guidance, use of the posterior mitral leaflet as a reference point to generate the corresponding bi-planar view is recommended (Figure 3). When using …
Publish Year: 2018
Author: Andrea Colli, David Adams, Alessandro Fiocco, Nicola Pradegan, Lorenzo Longinotti, Matteo Nadali, Di...
Show more
See More
The procedure is performed using the chest. A safety-net preparation of the femoral vessels is used NeoChord DS1000 system (NeoChord, Inc., Eden Praire, as described for transapical TAVI. MN) under guidance of direct 2D and 3D transesophageal echocardiography (TEE) (5,6) for both implantation and tension adjustment of the NeoChordae.
Show more
See More
multiple different methods in current use. The loop NeoChord technique provides a versatile and reproducible method that can be used for anterior, posterior, or bileaflet prolapse, as well as Barlow’s disease. Preoperative planning and careful intraoperative valvular assessment are used to determine the appropriate loop length.
Show more
See More
Jan 08, 2013 . “Receiving CE marking for the NeoChord device for implantation of artificial chordae tendinae via a transapical, off-pump procedure and beginning the TACT Registry are meaningful steps forward in the treatment of patients with severe mitral regurgitation.
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
Show more
See More
Oct 16, 2009 . Digital animation of beating-heart, sternal-sparing implantation of artificial chordae tendineae enabled by NeoChord's surgical device -- a minimally-invasiv...
Show more
See More
NeoChord Implantation (TOP-MINI) is a new MVR option that has been approved for patients presenting with severe mitral regurgitation (MR) due to leaflet(s) prolapse or flail (2-4). The procedure is performed using the NeoChord DS1000 system (NeoChord, Inc., Eden Praire, MN) under guidance of direct 2D and 3D transesophageal
Show more
See More
It is deployed through the vein using a transfemoral delivery catheter and navigated transeptally to the diseased native mitral valve. The NeoChord Nexus is an investigational device and is not commercially available.
Show more
See More
Other Section Step 1. A standard left lateral mini-thoracotomy is performed in the fifth intercostal space to access the left... Step 2. A transapical ventriculotomy is performed with an 11 scalpel blade and slightly dilated with a long straight... Step 3. …
Publish Year: 2015
Author: Andrea Colli, Fabio Zucchetta, Gianluca Torregrossa, Erica Manzan, Eleonora Bizzotto, Laura Besola, ...
Show more
See More
Trans-apical, echo-guided mitral valve (MV) repair using the NeoChord procedure has been shown to be safe and effective in correcting degenerative mitral regurgitation (MR) without concomitant annuloplasty (1-4). The NeoChord procedure has been standardized and is of reproducible quality.
Show more
See More
NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency. The NeoChord Artificial Chordae Delivery System, Model DS1000 , meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.
Show more
See More
NeoChord DS1000 is the most widely used technology in the field, with a solid procedural experience and good results in well‐selected patients. Its clinical use has been validated in Europe since 2012, while it is still under clinical investigation in the United States. Harpoon MVRe system is a novel technology, recently CE‐mark approved for
Show more
See More
NeoChord DS1000 is the most widely used technology in the field, with a solid procedural experience and good results in well-selected patients. Its clinical use has been validated in Europe since 2012, while it is still under clinical investigation in the United States.
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. This opens in a new window.
El-Eshmawi says half of the subjects will receive a mitral valve repair with the NeoChord device and the control group will receive repair using standard surgical techniques with cardiopulmonary bypass.
The first 50 patients of the TACT study are scheduled to undergo the NeoChord procedure during the first three months of this year. Dr. Giovanni Speziali, one of the proctors of the study from the University of Pittsburgh Medical Center, stated: